Home > Journals > Minerva Ortopedica e Traumatologica > Past Issues > Minerva Ortopedica e Traumatologica 2010 April;61(2) > Minerva Ortopedica e Traumatologica 2010 April;61(2):145-54

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA ORTOPEDICA E TRAUMATOLOGICA

A Journal on Orthopedics and Traumatology


Official Journal of the Piedmontese-Ligurian-Lombard Society of Orthopedics and Traumatology
Indexed/Abtracted in: EMBASE, Scopus, Emerging Sources Citation Index


eTOC

 

REVIEWS  CURRENT TRENDS AND CONTROVERSIES IN HIP DISORDERS - PART II


Minerva Ortopedica e Traumatologica 2010 April;61(2):145-54

language: English

Venous thromboembolic disease after total hip arthroplasty

Borris L. C.

Department of Orthopedics, Aarhus University Hospital, Aarhus, Denmark


PDF  


Venous thromboembolic (VTE) events are common complications following total hip arthroplasty (THA). In order to prevent these events there is a common agreement among orthopedic surgeons on the necessity to use some kind of thromboprophylaxis in hospital after THA. However, barriers exist to prescribing prophylaxis after discharge from hospital because of concerns about adherence, bleeding, adverse events and outpatient monitoring. This skepticism is based on the limitations of the existing prophylactic methods. New management approaches have, therefore, been in demand for many years in order to give surgeons and patients greater incentives to comply with prophylaxis guidelines and to provide adequate prophylaxis following discharge, where needed. Two new orally administered drugs with different attack points in the coagulation system have recently been launched on the markets in Europe and Canada: dabigatran etexilate, a direct thrombin inhibitor and rivaroxaban, a direct Factor Xa inhibitor. Both can be administered orally at a fixed dose, have a rapid onset of action, are well tolerated and need no regular monitoring. Both drugs have undergone clinical testing in THA patients in a number of well-designed phase III, randomized, controlled trials with enoxaparin (a low molecular weight heparin) in the comparator arm. The result of these trials has been that relative to enoxaparin dabigatran etexilate has demonstrated a non-inferior effectiveness and an equal safety and that rivaroxaban has demonstrated superiority without significantly increasing the rate of major bleeding in the prevention of VTE.

top of page

Publication History

Cite this article as

Corresponding author e-mail